Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $65.3 million.

  • Foghorn Therapeutics' Current Deferred Revenue rose 9559.97% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 9559.97%. This contributed to the annual value of $45.6 million for FY2024, which is 3200.0% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Current Deferred Revenue stood at $65.3 million for Q3 2025, which was up 9559.97% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Current Deferred Revenue ranged from a high of $65.3 million in Q3 2025 and a low of $15.0 million during Q1 2021
  • Over the past 5 years, Foghorn Therapeutics' median Current Deferred Revenue value was $32.8 million (recorded in 2022), while the average stood at $34.1 million.
  • In the last 5 years, Foghorn Therapeutics' Current Deferred Revenue skyrocketed by 129906.13% in 2021 and then plummeted by 1452.31% in 2023.
  • Foghorn Therapeutics' Current Deferred Revenue (Quarter) stood at $28.3 million in 2021, then increased by 15.9% to $32.8 million in 2022, then grew by 5.27% to $34.6 million in 2023, then soared by 32.0% to $45.6 million in 2024, then soared by 43.18% to $65.3 million in 2025.
  • Its last three reported values are $65.3 million in Q3 2025, $59.7 million for Q2 2025, and $51.7 million during Q1 2025.